117 related articles for article (PubMed ID: 38321884)
21. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
22. Salinomycin suppresses cancer cell stemness and attenuates TGF-β-induced epithelial-mesenchymal transition of renal cell carcinoma cells.
Liu L; Wang Q; Mao J; Qin T; Sun Y; Yang J; Han Y; Li L; Li Q
Chem Biol Interact; 2018 Dec; 296():145-153. PubMed ID: 30273566
[TBL] [Abstract][Full Text] [Related]
23. Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients.
Fendler A; Bauer D; Busch J; Jung K; Wulf-Goldenberg A; Kunz S; Song K; Myszczyszyn A; Elezkurtaj S; Erguen B; Jung S; Chen W; Birchmeier W
Nat Commun; 2020 Feb; 11(1):929. PubMed ID: 32066735
[TBL] [Abstract][Full Text] [Related]
24. Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.
Mizumoto A; Yamamoto K; Nakayama Y; Takara K; Nakagawa T; Hirano T; Hirai M
J Pharmacol Exp Ther; 2015 Nov; 355(2):152-8. PubMed ID: 26306766
[TBL] [Abstract][Full Text] [Related]
25. Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line.
Ueda K; Ogasawara S; Akiba J; Nakayama M; Todoroki K; Ueda K; Sanada S; Suekane S; Noguchi M; Matsuoka K; Yano H
PLoS One; 2013; 8(10):e75463. PubMed ID: 24116047
[TBL] [Abstract][Full Text] [Related]
26. Role of SIRT2 in Regulation of Stemness of Cancer Stem-Like Cells in Renal Cell Carcinoma.
Wei R; He D; Zhang X
Cell Physiol Biochem; 2018; 49(6):2348-2357. PubMed ID: 30261494
[TBL] [Abstract][Full Text] [Related]
27. Thymoquinone suppresses the proliferation of renal cell carcinoma cells via reactive oxygen species-induced apoptosis and reduces cell stemness.
Liou YF; Chen PN; Chu SC; Kao SH; Chang YZ; Hsieh YS; Chang HR
Environ Toxicol; 2019 Nov; 34(11):1208-1220. PubMed ID: 31298468
[TBL] [Abstract][Full Text] [Related]
28. Single cell dual adherent-suspension co-culture micro-environment for studying tumor-stromal interactions with functionally selected cancer stem-like cells.
Chen YC; Zhang Z; Fouladdel S; Deol Y; Ingram PN; McDermott SP; Azizi E; Wicha MS; Yoon E
Lab Chip; 2016 Aug; 16(15):2935-45. PubMed ID: 27381658
[TBL] [Abstract][Full Text] [Related]
29. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
[TBL] [Abstract][Full Text] [Related]
30. Malignant phenotype of renal cell carcinoma cells is switched by ukrain administration in vitro.
Gagliano N; Pettinari L; Aureli M; Martinelli C; Colombo E; Costa F; Carminati R; Volpari T; Colombo G; Milzani A; Dalle-Donne I; Gioia M
Anticancer Drugs; 2011 Sep; 22(8):749-62. PubMed ID: 21799470
[TBL] [Abstract][Full Text] [Related]
31. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Benitez A; Yates TJ; Shamaldevi N; Bowen T; Lokeshwar VB
J Urol; 2013 Jul; 190(1):285-90. PubMed ID: 23228386
[TBL] [Abstract][Full Text] [Related]
32. Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells.
Zhong Y; Guan K; Guo S; Zhou C; Wang D; Ma W; Zhang Y; Li C; Zhang S
Cancer Lett; 2010 Dec; 299(2):150-60. PubMed ID: 20846785
[TBL] [Abstract][Full Text] [Related]
33. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
[TBL] [Abstract][Full Text] [Related]
34. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
35. Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
Jiang XL; Zhang Y; Luo CL; Wu XH
Asian Pac J Cancer Prev; 2012; 13(12):6463-8. PubMed ID: 23464475
[TBL] [Abstract][Full Text] [Related]
36. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma.
Gao X; Jiang P; Zhang Q; Liu Q; Jiang S; Liu L; Guo M; Cheng Q; Zheng J; Yao H
J Exp Clin Cancer Res; 2019 Aug; 38(1):362. PubMed ID: 31426831
[TBL] [Abstract][Full Text] [Related]
37. CircRNA_001895 promotes sunitinib resistance of renal cell carcinoma through regulation of apoptosis and DNA damage repair.
Tan L; Huang Z; Chen Z; Chen S; Ye Y; Chen T; Chen Z
J Chemother; 2023 Feb; 35(1):11-18. PubMed ID: 34927575
[TBL] [Abstract][Full Text] [Related]
38. PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
Huang B; Fu SJ; Fan WZ; Wang ZH; Chen ZB; Guo SJ; Chen JX; Qiu SP
Cancer Lett; 2016 Jun; 376(1):148-54. PubMed ID: 27037060
[TBL] [Abstract][Full Text] [Related]
39. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T
Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582
[TBL] [Abstract][Full Text] [Related]
40. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
Zhang L; Xie D; Lei Y; Na A; Zhu L
Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
